Trails Edge Capital Partners »

Moonlake Immunot shares owned by Trails Edge Capital Partners

Quarter-by-quarter ownership of Moonlake Immunot (MLTX) shares owned by Trails Edge Capital Partners from 13F filings

Historical chart of Trails Edge Capital Partners investment in Moonlake Immunot

Tip: Access up to 7 years of quarterly data

All positions including Moonlake Immunot held by Trails Edge Capital Partners consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Moonlake Immunot by Trails Edge Capital Partners

Quarter filed Position value Share count Share price at filing
2026-06-30 $15M 750k 19.47

More positions owned by Trails Edge Capital Partners

Lb Pharmaceuticals Com Shs (LBRX)
Nurix Therapeutics (NRIX)
Immunocore Hldgs Ads (IMCR)
First Tracks Biotherapeutics Ord Shs (TRAX)
4d Molecular Therapeutics In (FDMT)
BioMarin Pharmaceutical (BMRN)
Design Therapeutics (DSGN)
Xenon Pharmaceuticals (XENE)
Mirum Pharmaceuticals (MIRM)
Insmed Com Par $.01 (INSM)
Cytokinetics Com New (CYTK)
Syndax Pharmaceuticals (SNDX)
Neurogene (NGNE)
Kailera Therapeutics Common Stock
Revolution Medicines (RVMD)

View all positions for Trails Edge Capital Partners

Top funds holding Moonlake Immunot

BVF
Deep Track Capital
Henderson Group
D. E. Shaw & Co
Cormorant Asset Management
Jupiter Topco
Logos Global Management
Weiss Asset Management LP[1
Citadel Advisors
Two Sigma Investments
MPM Oncology Impact Management
Vivo Capital
Jpmorgan Chase & Co
T. Rowe Price Associates
Jane Street

View all funds holding Moonlake Immunot